Union Minister of Agriculture and Farmers Welfare and Rural Development Shri Shivraj Singh Chouhan will dedicate India's first indigenous Inactivated H5N1 (Clade 2.3.2.1a) Highly Pathogenic Avian Influenza Vaccine for Chickens to the nation on November 20, 2026, at ICAR-National Institute of High Security Animal Diseases (ICAR-NIHSAD) in Bhopal.
The vaccine, developed indigenously by ICAR-NIHSAD, is the first of its kind in India specifically targeting the H5N1 HPAI virus of Clade 2.3.2.1a, which has been responsible for most bird flu outbreaks in chickens. Highly Pathogenic Avian Influenza causes nearly 100% mortality among infected birds and has led to major financial losses for poultry farmers through large-scale culling and trade restrictions.
Since the first detection of the disease in India in 2006, more than 500 combined outbreaks of H5N1 and H5N8 subtypes have been reported. The economic impact has been substantial, with the 2006 outbreak causing estimated direct and indirect losses of ₹2,200–3,000 crore. An outbreak in Manipur resulted in losses equivalent to 0.5% of the state's GDP. A major outbreak could reduce India's GDP growth by up to 1.5% and put over 20% of the country's poultry population at risk.
The disease also presents significant public health concerns, with the World Health Organization reporting 1,003 human cases of H5N1 avian influenza including 479 deaths across 25 countries since 2003. The Clade 2.3.2.1a strain has recently been detected in different animal species, including mammals, along with three human cases, highlighting the importance of controlling its spread. Currently, no specific commercial vaccine is available against this particular H5N1 virus clade, making the indigenous development crucial for India's poultry disease control efforts.